Big Pharma: a former insider’s view
There is no lack of criticisms frequently levelled against the international pharmaceutical industry (Big Pharma): excessive profits, dubious or even dishonest practices, exploiting the sick and selective use of research data. Neither is there a shortage of examples used to support such opinions. A recent book by Brody (Hooked: Ethics, the Medical Profession and the Pharmaceutical Industry, 2008) provides a précis of the main areas of criticism, adopting a twofold strategy: (1) An assumption that the special nature and human need for pharmaceutical medicines requires that such products should not be treated like other commodities and (2) A multilevel descriptive approach that facilitates an ethical analysis of relationships and practices. At the same time, Brody is fully aware of the nature of the fundamental dilemma: the apparent addiction to (and denial of) the widespread availability of gifts and financial support for conferences etc., but recognises that ‘Remove the industry and its products, and a considerable portion of scientific medicine’s power to help the patient vanishes’ (Brody 2008, p. 5). The paper explores some of the relevant issues, and argues that despite the identified shortcomings and a need for rigorous and perhaps enhanced regulation, and realistic price control, the commercially competitive pharmaceutical industry remains the best option for developing safer and more effective medicinal treatments. At the same time, adoption of a broader ethical basis for the industry’s activities, such as a triple bottom line policy, would register an important move in the right direction and go some way toward answering critics.
KeywordsBig Pharma Market manipulation Medicalization Pharmaceutical industry ethics Triple bottom line policy
Conflict of interest
Having worked in research & development for some 30 years the author is in receipt of an occupational pension from the pharmaceutical industry. He is not a spokesman for the industry and the views expressed are entirely his own.
- Angell, M. 2004. The truth about the drug companies. How they deceive us and what to do about it. New York: Random House.Google Scholar
- Arrow, K. 1963. Uncertainty and the welfare economics of medical care. The American Economic Review LIII 5: 941–973.Google Scholar
- Ashford, E. 2006. the inadequacy of our traditional conception of the duties imposed by human rights. Canadian Journal of Law and Jurisprudence XIX 2: 217–235.Google Scholar
- Baker, D. 2009. Free market myth. Boston Review January/February (online edition). Downloaded from : http://bostonreview.net July 2009.
- Brody, H. 2008. Hooked: Ethics, the medical profession and the pharmaceutical industry (Pbk.) Lanham, Maryland, USA: Rowman, & Littlefield Publishing, Inc.Google Scholar
- Burke, E. 1984. Reflections on the revolution in France, Conor Cruise O’Brien, ed. London: Penguin Books, 1984), pp. 151–152. Quoted in O’Neill (2005).Google Scholar
- Canguilhem, G. 1991. The normal and the pathological. New York: Zone Books.Google Scholar
- Chang, P.L. 2006. Who’s in the business of saving lives? Journal of Medicine and Philosophy 31: 465–482.Google Scholar
- Ciulla, J.B. 2007. The importance of leadership in shaping business values, chapter 6 In Corporate Ethics and Corporate Governance, eds. Zimmerli, W.C., K. Richter and M. Holzinger. Berlin: Springer.Google Scholar
- Civan, A. and B. Köksal. 2010. The effect of newer drugs on health spending: Do they really increase the costs? Health Economics 19(5): 581–595.Google Scholar
- Daniels, N. 2004. Justice, health and healthcare, chapter 1. In Health care policy, Shannon, T., ed. Oxford UK: Rowan and Littlefield Publishers Inc.Google Scholar
- Elkington, J. 1997. Cannibals with forks: the triple bottom line of 21st Century Business. Oxford: Capstone Publishers.Google Scholar
- Feinberg, J. 1980. Rights, justice and the bounds of liberty: Essays in social philosophy. Princeton: Princeton University Press.Google Scholar
- Finegold, D., P. Singer, A. Daar, C. Bensimon, M. Eaton, B. Godard, B. Knoppers, and J. Mackie. 2005. Bioindustry ethics. London: Elsevier Academic Press.Google Scholar
- Fox, N.J., and J. Ward. 2008. Pharma in the bedroom …and the kitchen…. The pharmaceuticalisation of daily life. Sociology of Health & Illness 30(6): 856–868.Google Scholar
- Goldman, A.H. 1980. Business ethics: Profits, utilities, and moral rights. Philosophy & Public Affairs 9(3): 260–286.Google Scholar
- Goldman, M. 2003. Pharmafocus. Downloaded from: www.inpharm.co./new/infernal-focus.
- Gray, J. 2008. It depends, pp. 8–11. In Does the free market corrode moral character? Thirteen views on the question. Pennsylvania: John Templeton Foundation.Google Scholar
- Hevey, R. and C-C. Ling. 2012. Global financial challenges: Opportunities for strengthening R&D research in targeted drug delivery. Future Medicinal Chemistry 4(1): 1–5.Google Scholar
- Huber, P. 2006. Of pills and profits: In defense of Big Pharma. Commentary. Manhattan Institute for Policy Research. Downloaded October 2010, from: www.manhattan-institute.org.
- Humber, J.W., and R.F. Almeder (eds.). 1997. What is disease? Totowa: Humana Press.Google Scholar
- Kassirer, J. 2005. On the take. How medicine’s complicity with big business can endanger your health. New York: Oxford University Press.Google Scholar
- Lane, C. 2007. Shyness: how normal behavior became a sickness. New Haven: Yale University Press.Google Scholar
- Larrère, C. 2010. Ethics and nanotechnology: The issue of perfectionism. HYLE- International Journal for Philosophy of Chemistry 16(1): 19–30.Google Scholar
- Lévy, B-H. 2008. Certainly. Or does it? pp. 28–30, In Does the free market corrode moral character? Thirteen views on the question. Pennsylvania: John Templeton Foundation.Google Scholar
- MacIntyre, A. 1999. Social structures and their threats to moral agency. Philosophy 74(3): 311–329.Google Scholar
- Markle, G., J. Petersen, and M. Wagenfeld. 1978. Notes from the cancer underground: Participation in the laetrile movement. Social Science & Medicine 12: 31–37.Google Scholar
- Mittra, J. 2005. Pharmaceutical industries: Do they prefer treatment to cure? The Biochemist 27(3): 32–34.Google Scholar
- Mullin, R. 2003. Drug development costs about $1.7 billion. Chemical Engineering News 81:8.Google Scholar
- Radoilska. L., and D. Scott. 2005. Trust in the Pharmaceutical Industry: A philosophical perspective. Report produced by the forum for philosophy in business, Faculty of Philosophy, University of Cambridge. Google Scholar
- Reisel, W., and L.M. Sama. 2003. The distribution of life-saving pharmaceuticals. Viewing the conflict between social efficiency and economic efficiency through a social contract lens. Business and Society Review 108(3): 365–387.Google Scholar
- Robinson, J. 2001. Prescription games. Money, ego and power inside the global pharmaceutical industry. London and Sydney: Simon & Schuster UK.Google Scholar
- Sandel, M. 2004. The case against perfectionism. The Atlantic online April: 1–11. Accessed March 2011.Google Scholar
- Savulescu, J., and N. Bostrom (eds.). 2009. Human enhancement. Oxford: Oxford University Press.Google Scholar
- Tuominen, N. 2010. Defensive patent protection strategies in the pharmaceutical industry—A response to a legal problem? Thesis for Degree of Master of European Studies, College of Europe, Bruges. Downloaded from: www.mayerbrown.com/public_docs/Thesis_Nicoleta_Tuominen.pdf. Universal Declaration of Human Rights. Adopted by UN General Assembly Resolution 217A (III) of 10 December 1948.
- Wolff, J. 2011. Pharmaceutical cost-control. A thought-piece for the future of healthcare in Europe conference 13 May 2011. Downloadable at http://www.ucl.ac.uk/european-institute/comment_analysis/commentary/healthcare (Accessed: October 1, 2011).
- Zall, M. 2001. The pricing puzzle. Modern Drug Discovery 4(3): 36–38, 41, 42.Google Scholar